NO20070140L - Mediatorer av revers kolesteroltransport for behandling av hyperkolesterolemi - Google Patents

Mediatorer av revers kolesteroltransport for behandling av hyperkolesterolemi

Info

Publication number
NO20070140L
NO20070140L NO20070140A NO20070140A NO20070140L NO 20070140 L NO20070140 L NO 20070140L NO 20070140 A NO20070140 A NO 20070140A NO 20070140 A NO20070140 A NO 20070140A NO 20070140 L NO20070140 L NO 20070140L
Authority
NO
Norway
Prior art keywords
hypercholesterolemia
treatment
mediators
cholesterol transport
reverse cholesterol
Prior art date
Application number
NO20070140A
Other languages
English (en)
Inventor
Jagadish C Sircar
Kashinatham Alisala
Igor Nikoulin
Victor Charles Vassar
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of NO20070140L publication Critical patent/NO20070140L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer preparater som er avpasset for å forbedre revers kolesteroltransport hos pattedyr. Preparatene er egnet for oral avlevering og er anvendelige ved behandling og /eller forebygging av hyperkolesterolemi, aterosklerose og relaterte kardiovaskulære sykdommer.
NO20070140A 2004-06-09 2007-01-08 Mediatorer av revers kolesteroltransport for behandling av hyperkolesterolemi NO20070140L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57822604P 2004-06-09 2004-06-09
US66736805P 2005-04-01 2005-04-01
PCT/US2005/020662 WO2005123770A1 (en) 2004-06-09 2005-06-09 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia

Publications (1)

Publication Number Publication Date
NO20070140L true NO20070140L (no) 2007-03-07

Family

ID=34982204

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070140A NO20070140L (no) 2004-06-09 2007-01-08 Mediatorer av revers kolesteroltransport for behandling av hyperkolesterolemi

Country Status (15)

Country Link
US (1) US20070004644A1 (no)
EP (1) EP1753782A1 (no)
JP (1) JP2008509228A (no)
KR (1) KR20070029198A (no)
AR (1) AR049081A1 (no)
AU (1) AU2005255013A1 (no)
BR (1) BRPI0511945A (no)
CA (1) CA2568543A1 (no)
IL (1) IL179302A0 (no)
MX (1) MXJL06000068A (no)
NO (1) NO20070140L (no)
PE (1) PE20060082A1 (no)
TW (1) TW200603795A (no)
UY (1) UY28952A1 (no)
WO (1) WO2005123770A1 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2410392C2 (ru) * 2009-02-16 2011-01-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН Дипептидные миметики нейротрофинов ngf и bdnf

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930024A (en) * 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
US3773946A (en) * 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
IL64542A0 (en) * 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPS60136512A (ja) * 1983-12-26 1985-07-20 Eisai Co Ltd 脂質代謝改善剤
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
DE3423166A1 (de) * 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
AU8334298A (en) * 1997-07-15 1999-02-10 Novo Nordisk A/S Nociceptin analogues
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
ATE384035T1 (de) * 1999-04-01 2008-02-15 Esperion Therapeutics Inc Ether-verbindungen, zusammensetzungen und ihre verwendung
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
FR2820435B1 (fr) * 2001-02-05 2004-02-27 Genfit S A Procedes d'identification de composes modulant le transport inverse du cholesterol
EP1615954A2 (en) * 2003-04-22 2006-01-18 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
KR20070026598A (ko) * 2004-06-09 2007-03-08 아바니르 파마슈티컬스 고지혈증 및 관련 질환의 치료를 위한 헤테로사이클 유도체
UY28951A1 (es) * 2004-06-09 2006-01-31 Avanir Pharmaceuticals Pequenas moleculas para el tratamiento de hipercolesterolemia y enfermedades relacionadas

Also Published As

Publication number Publication date
WO2005123770A1 (en) 2005-12-29
CA2568543A1 (en) 2005-12-29
AU2005255013A1 (en) 2005-12-29
EP1753782A1 (en) 2007-02-21
IL179302A0 (en) 2007-03-08
AR049081A1 (es) 2006-06-21
JP2008509228A (ja) 2008-03-27
PE20060082A1 (es) 2006-02-09
MXJL06000068A (es) 2007-04-10
TW200603795A (en) 2006-02-01
US20070004644A1 (en) 2007-01-04
BRPI0511945A (pt) 2008-01-29
KR20070029198A (ko) 2007-03-13
UY28952A1 (es) 2006-01-31

Similar Documents

Publication Publication Date Title
NO20070139L (no) Heterosykliske derivater for behandling av hyperlipidemi og relaterte sykdommer
NO20055474L (no) Mediatorer av revers kolesteroltransport for behandling av hyperkolesterolemi
EA200800834A1 (ru) Модуляторы метаболизма и лечение связанных с ним нарушений
NO20053845L (no) Gyraseinhibitorer og anvendelser derav
NO20064584L (no) Tetrahydropyridoindolderivater
WO2006045096A3 (en) Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
DK1789419T3 (da) Gyraseinhibitorer og anvendelser deraf
NO20070511L (no) Substituerte heteroaryl- og fenylsulfamoylforbindelser
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
NO20073025L (no) Dibenzylaminforbindelser og derivater
NO20073105L (no) Pyridazinonforbindelser
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
NO20075731L (no) Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjon
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
NO20064615L (no) Substituerte heteroaryl- og fenylsulfamoylforbindelser
WO2005110428A3 (en) Resistance-repellent retroviral protease inhibitors
NO20072934L (no) Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt
NO20071510L (no) 4-Amino-substituerte-2-substituerte-1,2,3,4-tetrahydrokinolinforbindelser
NO20076191L (no) Magnesiumsalter av HMG-COA reduktaseinhibitorer
NO20071706L (no) Koadministrering av Tigecycline og Digoxin.
NO20070140L (no) Mediatorer av revers kolesteroltransport for behandling av hyperkolesterolemi
NO20070141L (no) Sma molekyler for behandling av hyperkolesterolemi og relaterte sykdommer
DK1594456T3 (da) Anvendelse af en sammensætning indeholdende vitamin K1-oxid eller et derivat deraf til behandling og/eller forebyggelse af dermatologiske læsioner hos pattedyr
TW200700384A (en) Amorphous tegaserod maleate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application